Table 1. Comparison of patient clinicopathologic features based on EGFR mutation status.
EGFR mutated | EGFR wildtype | P-value | |
---|---|---|---|
Number of Cases, N | 142 | 140 | |
Stage 1 | 107 | 106 | |
Stage 2 | 13 | 13 | |
Stage 3 | 22 | 21 | |
Age at diagnosis, mean (SD) | 67.4 (9.7) | 67.2 (9.4) | 0.83 |
Stage 1 | 67.8 (9.5) | 67.3 (9.3) | 0.74 |
Stage 2 | 70.4 (6.8) | 66.1 (11.1) | 0.25 |
Stage 3 | 63.9 (11.4) | 67.0 (9.0) | 0.33 |
Gender—Female, N (%) | 104 (73%) | 96 (69%) | 0.46 |
Stage 1 | 77 (72%) | 72 (68%) | 0.62 |
Stage 2 | 9 (69%) | 11 (85%) | 0.64 |
Stage 3 | 18 (82%) | 13 (62%) | 0.26 |
% with high risk histologic features* | 47 (35%) | 42 (37%) | 0.81 |
Stage 1 | 29 (28%) | 27 (31%) | 0.79 |
Stage 2 | 8 (62%) | 8 (62%) | > 0.99 |
Stage 3 | 10 (53%) | 7 (54%) | > 0.99 |
% receiving standard of care** | 130 (92%) | 118 (86%) | 0.16 |
Stage 1 | 102 (95%) | 93 (89%) | 0.12 |
Stage 2 | 7 (54%) | 6 (46%) | > 0.99 |
Stage 3 | 21 (95%) | 19 (95%) | > 0.99 |
*High risk histologic features = visceral pleural invasion, lympho-vascular invasion, poor differentiation, histologic transformation, positive margins, lepidic spread or infarction/necrosis. **Standard of care defined per NCCN guidelines based on stage of disease. Stage I disease received definitive surgical management and stage II disease received surgery or radiation followed by adjuvant chemotherapy. For stage III standard of care treatment involved multi-disciplinary treatment. Patients with resectable disease received neoadjuvant chemotherapy +/− radiation followed by surgery. For unresectable disease, patients received chemoradiation followed by immunotherapy.